stockrowMedline Inc.
MDLN Healthcare Medical Instruments & Supplies
Medline Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.4 billion, up 11.5% from fiscal 2024.
- Revenue
- +14.1%
- Free cash flow
- +916.1%
- Total debt
- −23.7%
Quarter to September 2026, against a year earlier
Follow MDLN
Alert me
Medline Inc. (MDLN) Return on invested capital
Medline Inc.'s return on invested capital over the twelve months to 30 September 2026 was 17.8%, up 13.2 percentage points from fiscal 2025 (4.62%). That is above the Medical Instruments & Supplies industry median of 0.13% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 4.62% | 0.49 |
| FY2024 | 4.13% | 4.13 |
| FY2023 | 0.00% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| RMD ResMed Inc. compare | 22.8% |
| WST West Pharmaceutical Services, Inc. compare | 18.0% |
| MDLN Medline Inc. | 17.8% |
| ISRG Intuitive Surgical, Inc. compare | 17.0% |
| BDX Becton, Dickinson and Company compare | 3.89% |
| COO The Cooper Companies, Inc. compare | 3.17% |
| ALC Alcon compare | 2.38% |
| SOLV Solventum Corporation compare | 0.00% |
| BAX Baxter International Inc. compare | −1.05% |
| Medical Instruments & Supplies industry median | 0.13% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)